Related Experiment Videos
Aggressive angiomyxoma: irradiation for recurrent disease
W Rhomberg1, Z Jasarevic, R Alton
1Abteilung für Radioonkologie, Landeskrankenhaus Feldkirch, Austria.
Summary
Radiation therapy with the radiosensitizer razoxane effectively controlled recurrent aggressive angiomyxoma (AAM) in a patient. This treatment achieved local control for over two years, a significant improvement over previous surgical outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Soft Tissue Sarcomas
Background:
- Aggressive angiomyxoma (AAM) is a rare soft tissue tumor with a high recurrence rate, predominantly in the genital and pelvic regions.
- The etiology and pathogenesis of AAM remain largely unknown.
- AAM is sometimes classified as a low-grade sarcoma.
Observation:
- A case report details a 27-year-old male with a recurrent soft tissue neoplasm on his left lower extremity, initially misdiagnosed as myxolipoma.
- The patient underwent four surgical procedures due to repeated recurrences between 1993 and 1998.
- Following a palliative resection in February 1998, the patient received radiation therapy (56 Gy) with the radiosensitizer razoxane.
Findings:
- Radiation therapy resulted in tumor regression, although precise measurement was difficult.
- Local control was maintained for over two years post-treatment, exceeding previous recurrence-free intervals.
- This represents the first reported instance of therapeutic irradiation for recurrent aggressive angiomyxoma.
Implications:
- Combined radiation therapy and razoxane show promise for controlling recurrent AAM.
- Further research is needed to determine if radiation alone could achieve similar outcomes.
- This approach may offer a new therapeutic option for managing challenging AAM cases.